

10/31/01
jc698 U.S. PTO

12-06-01

A
SEQUENCE
JC50003211

Please type a plus sign (+) inside this box → +

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032U S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	A013 US CON
First Inventor	Browning, Jeffrey L. et al.
Title	Soluble Lymphotoxin-Beta Receptors and
Express Mail Label No.	EL543620827US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 70]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets]
5. Oath or Declaration [Total Pages]
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
11. English Translation Document (if applicable)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent
Comin. re: calculation of claims...
17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP)
Prior application information *Examiner* F. Vander Vegt
of prior application No.: 09/299,139
Group Art Unit 1644

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)			<input type="checkbox"/> or <input checked="" type="checkbox"/> Correspondence address below
Name	Niki D. Cox, Esq.			
	BIOGEN, INC.			
Address	14 Cambridge Center			
City	Cambridge	State	MA	Zip Code
Country	USA	Telephone	(617) 679-2079	Fax (617) 679-2838
Name (Print/Type)	Niki D. Cox	Registration No. (Attorney/Agent)	42,446	
Signature	<i>Niki D. Cox</i>			Date 10-31-01

Burden Hour Statement: This form is estimated to take 0 2 hours to complete Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U S Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)

740

Complete if Known

Application Number	Continuation of 09/299,139
Filing Date	HEREWITH
First Named Inventor	Browning, Jeffrey L. et al.
Examiner Name	G. Bansal
Group Art Unit	1642
Attorney Docket No.	A013 US CON

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to
 Deposit Account Number **02-2327**
 Deposit Account Name _____
 Charge Any Additional Fee Required
 Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status
 See 37 CFR 1.27
2. Payment Enclosed:
 Check Credit card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101	740	201 370 Utility filing fee	740
106	330	206 165 Design filing fee	
107	510	207 255 Plant filing fee	
108	740	208 370 Reissue filing fee	
114	160	214 80 Provisional filing fee	
SUBTOTAL (1) (\$)		740	

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
1	-20** = 0	X	= 0
Independent Claims	1	- 3** = 0	X = 0
Multiple Dependent			= 0

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103	18	203 9 Claims in excess of 20
102	84	202 42 Independent claims in excess of 3
104	280	204 140 Multiple dependent claim, if not paid
109	84	209 42 ** Reissue independent claims over original patent
110	18	210 9 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)		0

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205 65 Surcharge - late filing fee or oath	
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	
139	130	139 130 Non-English specification	
147	2,520	147 2,520 For filing a request for ex parte reexamination	
112	920*	112 920* Requesting publication of SIR prior to Examiner action	
113	1,840*	113 1,840* Requesting publication of SIR after Examiner action	
115	110	215 55 Extension for reply within first month	
116	400	216 200 Extension for reply within second month	
117	920	217 460 Extension for reply within third month	
118	1,440	218 720 Extension for reply within fourth month	
128	1,960	228 980 Extension for reply within fifth month	
119	320	219 160 Notice of Appeal	
120	320	220 160 Filing a brief in support of an appeal	
121	280	221 140 Request for oral hearing	
138	1,510	138 1,510 Petition to institute a public use proceeding	
140	110	240 55 Petition to revive - unavoidable	
141	1,280	241 640 Petition to revive - unintentional	
142	1,280	242 640 Utility issue fee (or reissue)	
143	460	243 230 Design issue fee	
144	620	244 310 Plant issue fee	
122	130	122 130 Petitions to the Commissioner	
123	50	123 50 Processing fee under 37 CFR 1.17(q)	
126	180	126 180 Submission of Information Disclosure Stmt	
581	40	581 40 Recording each patent assignment per property (times number of properties)	
146	740	246 370 Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249 370 For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279 370 Request for Continued Examination (RCE)	
169	900	169 900 Request for expedited examination of a design application	
Other fee (specify) _____			
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)	0


SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Niki D. Cox, Esq.	Registration No. (Attorney/Agent)	42,446	Telephone	(617) 679-2079
Signature	<i>Niki D. Cox</i>			Date	10-31-01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail Label No. EL543620827US in an envelope addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on this 31st day of October, 2001.



Patricia Hofstetter

A013 US CON/NDC/jss

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Browning et al.

Examiner: Unassigned

Filing Date: On even date herewith

Group Art Unit: Unassigned

Serial No.: Unassigned

For: Soluble Lymphotoxin-Beta Receptors And Anti-Lymphotoxin Receptor And Ligand Antibodies As Therapeutic Agents For The Treatment Of Immunological Diseases

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express mail, under Express mail No. EL543620827US to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231, on:

31 October 2001

Date

Patricia Hofstetter

Patricia Hofstetter

Communication


Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please cancel in this application original claims 2-50 of the prior application before calculating the filing fee. (At least one original independent claim has been retained for filing purposes.)

A Preliminary Amendment is being filed concurrently with this application. Claims added by the Preliminary Amendment have been properly numbered consecutively beginning with the number next following the highest number of **original** claims in the prior application.

Respectfully submitted,

Date: 10-31-01

Niki Cox
 Niki Cox, Esq. Reg. No. 42,446

BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)

IN THE UNITED STATES RECEIVING OFFICE

In re application of: Browning, J. L. et al. U.S. Serial No.: Unassigned

U.S. Filing date: Herewith Group Art Unit: Unassigned

Continuation of
Serial No.: 09/299,139 (Examiner G. Bansal, Group Art Unit 1642)

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for
the Treatment of Systemic Lupus Erythematosus (as amended)

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence, together with all items referred to herein, is being deposited with the United States Post Office as Express Mail Label No. EL543620827US in an Express Mail Envelope addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, DC 20231 on the date shown below.

31 October 2001

Date

Patricia Hofstetter

Patricia Hofstetter

Box Patent Applications
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith is a diskette containing a machine readable copy of the Sequence Listing of the Paper Sequence listing for the above-referenced Patent Application as filed herewith.

The Sequence Listing diskette submitted herewith is the same as the paper form of the Sequence Listing submitted herewith.

Respectfully submitted,

Date: 10-31-01

Niki D. Cox

Niki D. Cox

Reg. No. 42,446

BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 679-2079